Porton Pharma Solutions Ltd. (SHE:300363)
China
· Delayed Price · Currency is CNY 21.42
+0.35 (1.66%)
Mar 10, 2026, 2:15 PM CST
Porton Pharma Solutions Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -1.41 | -287.75 | 266.86 | 2,005 | 523.92 | 324.42 | Upgrade
|
| Depreciation & Amortization | 395.59 | 395.59 | 349.11 | 259.67 | 192.2 | 131.12 | Upgrade
|
| Other Amortization | 50.22 | 50.22 | 30.27 | 6.88 | 4.26 | 0.55 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.77 | 0.77 | -0.54 | -0.1 | 3.21 | -0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 92.57 | 92.57 | 58.13 | 18.63 | 16.22 | 7.07 | Upgrade
|
| Loss (Gain) From Sale of Investments | 49.24 | 49.24 | 7.76 | 28.18 | 6.79 | -14.91 | Upgrade
|
| Provision & Write-off of Bad Debts | 20.28 | 20.28 | -35.24 | 33.12 | 43.47 | 3.78 | Upgrade
|
| Other Operating Activities | -142.89 | 11.69 | 23.12 | -50.74 | -1.13 | 74.2 | Upgrade
|
| Change in Accounts Receivable | -80.55 | -80.55 | 954.72 | -330.48 | -736.71 | -69.98 | Upgrade
|
| Change in Inventory | -105.9 | -105.9 | 130.04 | -163.58 | -315.56 | -112.55 | Upgrade
|
| Change in Accounts Payable | 289.92 | 289.92 | -1,173 | 732.54 | 756.73 | 152.46 | Upgrade
|
| Operating Cash Flow | 537.29 | 405.53 | 629.06 | 2,564 | 480.17 | 504.37 | Upgrade
|
| Operating Cash Flow Growth | - | -35.53% | -75.47% | 434.06% | -4.80% | 43.54% | Upgrade
|
| Capital Expenditures | -364.83 | -490.58 | -1,130 | -1,173 | -776.97 | -393.97 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.77 | 2.53 | 2.35 | 1.34 | 6.99 | 0.84 | Upgrade
|
| Cash Acquisitions | - | - | - | -233.33 | -171.1 | - | Upgrade
|
| Investment in Securities | -603.55 | -15 | -20 | -26.5 | 15.51 | -23.8 | Upgrade
|
| Other Investing Activities | 8.79 | 3.1 | 32.76 | -4.65 | 9.4 | -12.33 | Upgrade
|
| Investing Cash Flow | -955.82 | -499.95 | -1,115 | -1,436 | -916.17 | -429.26 | Upgrade
|
| Long-Term Debt Issued | - | 237.98 | 1,119 | 1,345 | 414.64 | 1,127 | Upgrade
|
| Long-Term Debt Repaid | - | -328.64 | -574.14 | -1,266 | -353.43 | -1,058 | Upgrade
|
| Total Debt Repaid | -529.19 | -328.64 | -574.14 | -1,266 | -353.43 | -1,058 | Upgrade
|
| Net Debt Issued (Repaid) | -242.83 | -90.66 | 544.43 | 78.19 | 61.2 | 69.2 | Upgrade
|
| Issuance of Common Stock | - | - | 1.21 | 16.1 | 65.01 | 41.16 | Upgrade
|
| Repurchase of Common Stock | -9.87 | -9.87 | -19.39 | -100 | - | - | Upgrade
|
| Common Dividends Paid | -15.79 | -301.5 | -626.57 | -129.08 | -82.76 | -82.53 | Upgrade
|
| Other Financing Activities | 14.46 | -11.71 | -28.22 | 395.63 | 306.76 | 24.12 | Upgrade
|
| Financing Cash Flow | -254.02 | -413.74 | -128.54 | 260.84 | 350.22 | 51.95 | Upgrade
|
| Foreign Exchange Rate Adjustments | 12.27 | 4.51 | 55.29 | 49.04 | -9.05 | -26.7 | Upgrade
|
| Net Cash Flow | -660.28 | -503.66 | -558.95 | 1,438 | -94.83 | 100.36 | Upgrade
|
| Free Cash Flow | 172.46 | -85.06 | -500.81 | 1,391 | -296.8 | 110.4 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | -37.38% | Upgrade
|
| Free Cash Flow Margin | 5.03% | -2.82% | -13.66% | 19.78% | -9.56% | 5.33% | Upgrade
|
| Free Cash Flow Per Share | 0.32 | -0.16 | -0.92 | 2.56 | -0.55 | 0.20 | Upgrade
|
| Cash Income Tax Paid | - | -67.14 | 30.17 | -137.27 | -73.82 | -6.34 | Upgrade
|
| Levered Free Cash Flow | 2.1 | -157.27 | -1,174 | 905.7 | -513.5 | 111.79 | Upgrade
|
| Unlevered Free Cash Flow | 38.43 | -118.48 | -1,146 | 923.03 | -499.94 | 127.03 | Upgrade
|
| Change in Working Capital | 72.91 | 72.91 | -70.41 | 263.33 | -308.76 | -21.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.